US Stock MarketDetailed Quotes
MURA Mural Oncology
- 4.040
- +0.110+2.80%
Close Nov 27 16:00 ET
- 4.020
- -0.020-0.50%
Post 20:01 ET
68.92MMarket Cap-447P/E (TTM)
4.099High3.900Low330.42KVolume4.020Open3.930Pre Close1.31MTurnover2.40%Turnover RatioLossP/E (Static)17.06MShares6.25052wk High0.40P/B55.65MFloat Cap2.88052wk Low--Dividend TTM13.77MShs Float57.200Historical High--Div YieldTTM5.07%Amplitude2.880Historical Low3.973Avg Price1Lot Size
About Mural Oncology Company
Mural Oncology Plc is a clinical-stage oncology company, which engages in the business of discovering and developing immunotherapies for patients with cancer. Its lead product candidate is the Nemvaleukin Alfa which is an interleukin-2 cytokine designed to capture and expand therapeutic benefits of high-dose recombinant human IL-2. The company was founded on May 31, 2017 and is headquartered in Dublin, Ireland.
Company Profile
SymbolMURA
Company NameMural Oncology
Listing DateNov 6, 2023
Founded2017
CEODr. Caroline Loew, PhD
MarketNASDAQ
Employees117
Fiscal Year Ends12-31
Address10 Earlsfort Terrace
CityDublin
ProvinceDublin
CountryIreland
Zip Code2
Phone353-1-905-8020
Websitehttp://www.muraloncology.com
Company Executives
- Name
- Position
- Salary
- Dr. Caroline Loew, PhD
- Chief Executive Officer and Director
- 2.52M
- Adam D. Cutler
- Chief Financial Officer and Principal Accounting Officer
- 743.18K
- Vicki L. Goodman
- Chief Medical Officer
- 705.58K
- Maiken Keson-Brookes
- Chief Legal Officer
- --
- Scott T. Jackson, M.B.A.
- Chairman of the Board
- 65.97K
- Benjamin J. Hickey, M.B.A.
- Independent Director
- 51.79K
- Dr. Francis M. Cuss, F.R.C.P.,M.B.
- Independent Director
- 58.63K
- Sachiyo Minegishi, M.B.A.
- Independent Director
- --
- Dr. George S. Golumbeski, PhD
- Independent Director
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data